Membership to CPACT will allow Johnson and Johnson to
benefit from developments in process understanding and control of continuous
manufacturing processes for existing and new modalities. Additionally, Johnson
and Johnson will be enabled to access the extensive research that is currently
being undertaken at leading Universities and partner companies. The prospect to
set direction for future research projects and create new cross-pharma
collaborations is very appealing. It is appealing that membership will provide
the ability for Johnson and Johnson staff to access the library of data, papers
and lectures will assist with their ongoing development as professionals, which
is a big priority for the company. The networking opportunities that will be
available for staff to engage with other members will also allow information
and ideas to flow. This can only be seen as a real positive outcome for current
and future patients worldwide
Andrew Anderson